Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LRN Sponsors 2025 Nordic Ethics & Compliance Survey to Advance Region-Specific Insights on Responsible Business Conduct24.11.2025 11:00:00 EET | Press release
LRN Corporation, a leader in ethics and compliance (E&C) solutions, announced its sponsorship of the 2025 Nordic Ethics & Compliance Survey, an annual study by Nordic Business Ethics examining how organizations across the Nordic region integrate ethics, responsibility, and compliance into daily decision-making. LRN’s sponsorship supports the survey’s mission to highlight regional insights that enrich global understanding of workplace ethics. The partnership reflects LRN’s belief that effective E&C programs are not a one-size-fits-all solution and must be informed by regional cultural norms and organizational identity. The survey data shows that while Nordic organizations excel in values-driven ethics, their experience mirrors a global trend of increased regulatory expectations and company growth straining operational systems and governance structures. “Nordic organizations demonstrate what it looks like when ethics is not a mandate but a mindset,” said Danny Collins, SVP EMEA at LRN. “
IonQ Appoints Dr. Marco Pistoia as CEO of IonQ Italia to Spearhead Strategic Quantum Initiatives Across the Country24.11.2025 10:00:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced the appointment of Dr. Marco Pistoia, Ph.D., as Chief Executive Officer of IonQ Italia S.r.l., a wholly owned subsidiary. Dr. Pistoia will lead IonQ’s strategic initiatives in Italy, building on the company’s momentum as the world’s only full-stack quantum platform provider across quantum computing, quantum networking, quantum sensing, and quantum security. IonQ Italia will help establish Italy as a dynamic powerhouse in the global quantum landscape. Dr. Pistoia and his team will focus on expanding access to IonQ’s advanced quantum systems for Italian enterprises, research institutions, and government partners. The team will be tasked with driving innovation in quantum applications for key sectors such as finance, energy, aerospace, defense, pharmaceuticals, and advanced manufacturing. “Italy is a strategic pillar in IonQ’s global platform strategy, and Dr. Pistoia’s appointment reflects our unwavering commitment t
Global Youth Invited To Apply for Doha Debates Ambassador Program24.11.2025 08:45:00 EET | Press release
Qatar Foundation’s Doha Debates is inviting global youth ages 18–26 to apply for the eighth cohort of its international ambassador program. This 12-week virtual experience empowers participants to engage in constructive dialogue, collaborate on solutions to global challenges and form lasting relationships with other emerging leaders. The application deadline is December 15, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123068415/en/ Global youth are invited to apply for the Doha Debates Ambassador Program, a unique virtual experience that equips young changemakers with communication, collaboration, and problem-solving skills. (Photo: AETOSWire) The upcoming cohort begins with a four-week Community of Practice from January 20 to February 10, 2026, followed by the official Ambassador Program from February 17 to April 7, 2026. Participants will take part in weekly online workshops led by facilitation expert Dr. Brando
Brown Brothers Media Acquires European Startup Media Platform Silicon Canals24.11.2025 04:23:00 EET | Press release
Brown Brothers Media, a Singapore-based digital publisher, announces the acquisition of SiliconCanals.com, the European technology startup media platform and community founded by Remco Janssen and operated under Proudly Media. The six-figure, asset-based deal marks a new chapter for the 11-year-old Dutch media brand, which has grown into one of Europe’s leading voices in the startup and innovation ecosystem. Founded in 2014, Silicon Canals has established itself as a go-to source for news and insights on Europe’s tech, venture capital, and startup scene. The acquisition follows recent shifts in the European tech media landscape, including the closure of The Next Web’s editorial operations and MeOut Group’s earlier acquisition of EU-Startups. “After more than a decade building Silicon Canals into a trusted platform connecting Europe’s founders, innovators, and investors, it was time to pass the baton to a full-fledged, long-term media house,” said Remco Janssen, founder and CEO of Proud
IFF Introduces Smart Dosing Robot to Transform Fragrance Production24.11.2025 03:00:00 EET | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences, has implemented the Colibri robot in its Chin Bee production facility. This advanced industrial dosing system can produce fragrance sample batches on demand in minutes, reimagining and expediting the fragrance development journey for local, regional and global customers in Greater Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123090457/en/ Photo credit: IFF - Colleagues at IFF Chin Bee with the site's new smart-dosing robot. The new robotic system, installed at the company's cross-category Scent and Taste production plant in Chin Bee, Singapore, accelerates the path from ideation to formulation for fragrance creation. Replacing the previous system, it handles multiple ingredients simultaneously, operates four times faster and significantly boosts automation. This improved capability means more capacity, faster sample
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom